Loading cancer entity…
Loading cancer entity…
Clinical trials
4,033 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (699)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05241093 | A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | unknown | Phase 2 | 18 | Tarapeutics Science Inc.INDUSTRY | 1 | Apr 10, 2025 | clinicaltrials |
| NCT05272293 | Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Children/Young Adults With AML | unknown | Phase 1 / Phase 2 | 15 | Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyOTHER | 1 | Aug 28, 2024 |
| clinicaltrials |
| NCT05334693 | Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML | unknown | Phase 1 / Phase 2 | 15 | Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT05605379 | CML Pediatric ITK Response According to Molecular Identification at Diagnosis(CML Piramid) | unknown | — | 88 | University Hospital, BordeauxOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT06553638 | Evaluation of the Prognostic Impact of Decreased Serum beta2 Microglobulin in the First Year of Follow-up of Myeloproliferative Neoplasia (PRODIGE)(PRODIGE) | unknown | — | 50 | University Hospital, BrestOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT02897297 | Myeloproliferative Neoplastic Diseases Observatory From Brest(OBENE) | unknown | — | 1,000 | University Hospital, BrestOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT06263387 | Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine(VENAZA) | unknown | — | 230 | French Innovative Leukemia OrganisationOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT06512610 | ELN 2022 in MENAFC ( Middle Eastern or North Coast of Africa ) Patients With Newly AML | unknown | — | 100 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT03450512 | Incidence of Neutropenic Enterocolitis Study in Acute Myeloid Leukemia Patients During Intensive Therapy(DECLAM) | unknown | — | 170 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT04365179 | Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML | unknown | Phase 1 | 18 | Immune System Key LtdINDUSTRY | 1 | Jul 10, 2024 | clinicaltrials |
| NCT06486350 | IL-6: A Marker for AML Chemo Sensitivity | unknown | — | 72 | Fujian Medical University Union HospitalOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06481332 | Diagnostic Characterization and Evolution of "Triple Negative" Thrombocytosis (CASTETTE)(CASTETTE) | unknown | — | 300 | University Hospital, BrestOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT06481345 | Characterization of Myeloproliferative Neoplasia With a Mutated IDH, SRSF2 or SF3B1 Allele (CARPEDIEM)(CARPEDIEM) | unknown | — | 300 | University Hospital, BrestOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT06476535 | Observatory of Patients With MyeloProliferative Neoplasm Treated With Anti-inflammatory Immunotherapy(OPIUM) | unknown | — | 100 | University Hospital, BrestOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06469047 | Relationship Between Serum N/OFQ and Acute Myeloid Cell Leukemia(RBSNAAMCL) | unknown | — | 80 | Second Hospital of Shanxi Medical UniversityOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT02061800 | CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant | unknown | Phase 1 / Phase 2 | 14 | Diane GeorgeOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05304156 | Single-cell Dynamic Profiling in Adults With Newly Diagnosed Acute Myeloid Leukemia Treated With Intensive Chemotherapy. A THEMA Study"(DYNHAEMICS) | unknown | — | 200 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT01305499 | A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML) | unknown | Phase 2 | 52 | Hetty CarrawayOTHER | 1 | May 28, 2024 | clinicaltrials |
| NCT05241106 | A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | unknown | Phase 2 | 15 | Tarapeutics Science Inc.INDUSTRY | 1 | May 14, 2024 | clinicaltrials |
| NCT04655118 | Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis | unknown | Phase 2 | 121 | Telios Pharma, Inc.INDUSTRY | 13 | May 10, 2024 | clinicaltrials |
| NCT05832320 | Optimum Induction Therapy of Low-risk APL | unknown | N/A | 74 | Peking University People's HospitalOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT06251102 | Real-world Ruxolitinib Experience in PV(REVIEW) | unknown | — | 153 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 0 | May 9, 2024 | clinicaltrials |
| NCT05758610 | A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients | unknown | Phase 1 | 60 | Shengke Pharmaceuticals (Jiangsu) Limited, ChinaINDUSTRY | 1 | May 8, 2024 | clinicaltrials |
| NCT06367673 | Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia | unknown | Phase 1 | 24 | Zhejiang UniversityOTHER | 1 | Apr 18, 2024 | clinicaltrials |
| NCT04460950 | Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid Neoplasms | unknown | — | 237 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT03481868 | EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors(EPIK) | unknown | N/A | 160 | University Hospital, Clermont-FerrandOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT04470947 | Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies(EXALT-2) | unknown | — | 150 | Medical University of ViennaOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT06285136 | Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult | unknown | Phase 2 / Phase 3 | 40 | The Second Affiliated Hospital of Kunming Medical UniversityOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT02192619 | National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup | unknown | — | 500 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT06246006 | Functional Characterization of Thrombopoietin/cMPL Receptor Mutations in Myeloproliferative Neoplasia(MPL - NPM) | unknown | — | 30 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT04358393 | A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS | unknown | Phase 1 / Phase 2 | 69 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Feb 1, 2024 | clinicaltrials |
| NCT06233890 | The Analysis of Fatigue on Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia(TIRE) | unknown | — | 50 | Imperial College Healthcare NHS TrustOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT06218771 | A Study of TQB3454 Tablets in Patients With Blood Tumors | unknown | Phase 1 / Phase 2 | 80 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jan 23, 2024 | clinicaltrials |
| NCT04284228 | Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT | unknown | Phase 1 / Phase 2 | 22 | NexImmune Inc.INDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT06188182 | D-index as a Predictor of Complication of Treatment of Patients With Acute Myeloid Leukemia | unknown | — | 60 | Assiut UniversityOTHER | 0 | Jan 3, 2024 | clinicaltrials |
| NCT06177366 | A New Blood Score for Myelofibrosis Staging(FIBROMOELLE) | unknown | — | 120 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Dec 20, 2023 | clinicaltrials |
| NCT06162325 | Venetoclax in Combination With Standard Induction and Consolidation Chemotherapy in Newly Diagnosed Young AML Patients | unknown | — | 45 | Peking Union Medical College HospitalOTHER | 1 | Dec 8, 2023 | clinicaltrials |
| NCT04663100 | Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence | unknown | N/A | 30 | University of TennesseeOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT03193281 | KISS Study: Kinase Inhibition With Sprycel Start up(KISS) | unknown | Phase 2 | 91 | University of Auckland, New ZealandOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03896854 | CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | unknown | Phase 1 / Phase 2 | 15 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Nov 29, 2023 | clinicaltrials |
| NCT04257175 | CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression | unknown | Phase 2 / Phase 3 | 10 | Sheba Medical CenterOTHER_GOV | 1 | Nov 28, 2023 | clinicaltrials |
| NCT04989335 | Bisantrene Combination for Resistant AML | unknown | Phase 2 | 29 | Sheba Medical CenterOTHER_GOV | 1 | Nov 28, 2023 | clinicaltrials |
| NCT05918198 | Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia | unknown | Phase 2 | 52 | Peking University People's HospitalOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT06141304 | Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT | unknown | Phase 2 | 28 | The First Hospital of Jilin UniversityOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT06121765 | Metabolic Alternation and Clinicohematological Characteristic in Chronic Phase CML in Patient Treated With TKI | unknown | — | 45 | Assiut UniversityOTHER | 0 | Nov 8, 2023 | clinicaltrials |
| NCT04739826 | Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia | unknown | — | 491 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 3, 2023 | clinicaltrials |
| NCT06105658 | Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AML | unknown | Phase 2 | 20 | Anhui Provincial HospitalOTHER_GOV | 1 | Oct 30, 2023 | clinicaltrials |
| NCT04964518 | A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML) | unknown | Phase 1 / Phase 2 | 24 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Oct 25, 2023 | clinicaltrials |
| NCT05504408 | Observational Study for the Evaluation of Incidence of Systemic Mastocytosis in t(8;21) Acute Myeloid Leukemia | unknown | — | 200 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Apr 10, 2025source: clinicaltrials